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Abstract: Betulonic acid belongs to the pentacyclic triterpenic derivative class and can be
obtained through the selective oxidation of betulin. In this study we set obtaining several
functionalized derivatives of this compound by its condensation with several amino compounds
such as aminoguanidine, hydroxylamine, n-butylamine and thiosemicarbazide as our goal. The
functionalization of the parent compound led to several molecules with antiproliferative potential,
the most promising being 3–2-carbamothioylhydrazonolup-20(29)-en-28-oic acid.
Keywords: betulonic acid derivatives; triterpene; thermal analysis; synthesis; biological activity;
MTT assay
1. Introduction
Naturally occurring compounds have always been an important source of pharmacologically-active
molecules, associated with numerous biological targets and receptors. The importance of studying
naturally occurring compounds is also sustained by the fact that most plants are accessible resources,
the main problems consisting only in separation and purification of the bioactive derivatives contained
therein, which can be realized by employing numerous different instrumental and experimental
techniques [1–3]. Among all naturally occurring compounds, triterpenoids have been intensely
studied in the last decades, since these compounds are widely distributed in numerous plants and
possess important biological activities [4–9].
Betulin-skeleton compounds (including acids, aldehydes and their functionalized derivatives)
are well studied and recent references for numerous biological activities are reported [10,11], such
as treatment of liver fibrosis [12], proapoptotic and inhibition of cell migration in cancer [13,14],
antitumour [15,16], anti-mycobacterial [17], hypoglycemic [18], effective adjuvant treatment option in
pruritic dry skin [19], antiviral effect [20] and also immunomodulatory [21] and anti-inflammatory
activities [22].
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In the field of functionalization and evaluation of biological activities, betulonic acid and its
derivatives are by far less studied and reported in literature compared to other triterpenoids. Betulonic
acid (or lup-20(29)-en-3-oxo-28-oic, BetO, Figure 1)) and some of its derivatives were previously
evaluated for biological activities, showing antiviral [23,24], antitumor and antineoplastic [25,26],
hepatoprotective [27], anti-inflammatory [28,29], anti-HCMV activity [30], antimicrobial [31] and
immunotropic effects [32].
Figure 1. Structural formula of betulonic acid (BetO).
The synthesis and functionalization of betulonic acid was previously reported in the literature
by some authors, mainly focusing on physico-chemical investigation results, but some correlations
with biological activities are available as well [29,33–35]. With this consideration in mind, we set as
our goal the physico-chemical characterization and a preliminary evaluation of the biological activity
of four derivatives obtained by functionalization of betulonic acid at position 3 via condensation with
amino compounds. Compound C2 was previously reported by Flekhter et al. in 2004 [34] and later by
Genet et al. in 2010 [36]. The derivative C1 was quite recently evaluated as an inhibitor of osteoclast
differentiation [37].
2. Results and Discussion
2.1. Synthesis
The syntheses of the functionalized derivatives of betulonic acid were carried out in anhydrous
organic solvents like pyridine (C1, C2), toluene (C3) or ethanol (C4), using as starting material betulonic
acid obtained from betulin by a modified Jones oxidation method, previously reported, along with
the spectroscopic data and purity, by Ledeti and Bercean [33]. The functionalization of BetO was
carried out in the 3-oxo position by condensation with several amino compounds, like aminoguanidine,
hydroxylamine, n-butylamine and thiosemicarbazide, used in molar ratios ranging from 1:1 up to 1:2.
2.2. Characterization of Compounds
2.2.1. Physico-Chemical Data
The NMR data for the starting material used (BetO) was previously reported by or our group [33],
proving the purity of the starting compound. The physico-chemical characteristics of each compound
are presented in Table 1 (Experimental Section).
The spectra of these triterpenic substances are very similar (Figure 2). For all compounds, the
strong band in the 1712–1690 cm´1 range is identified as the νas(COO) vibration . The band assigned
to the vibration of νs(COO) is observed in the 1460–1385 cm´1 range. In the case of C1 and C2, the
symmetrical carboxyl group vibrations are split into two peaks. In the IR spectra of these compounds,
several vibrations characteristic of the triterpenic moieties are also present. The characteristic bands
attributed to the C=N stretching vibration are found at 1642 cm´1 for compounds C1–C3, respectively,
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and 1640 cm´1 for derivative C4, and this is in good agreement with the data mentioned in the
literature (between 1610 and 1665 cm´1) [38].
Figure 2. FTIR spectra of the analyzed compounds: (a) starting material BetO; (b) derivative C1;
(c) derivative C2; (d) derivative C3; (e) derivative C4.
In compound C2, the oxime functional group (C=N-OH) is represented by the vibrations at
ν = 3300 cm´1 for the O-H stretch; 1642 cm´1 for the C=N stretch and 945 cm´1 for the N-O bond,
respectively. For compound C1, the amino group is evidenced by the two stretching vibrations peaks
found in the 3400–3300 cm´1 range. The N=C-N stretching vibration peak appears at 1374 cm´1, and
the sharp bands in the 1160–1110 cm´1 interval correspond to the N-N stretching of the hydrazinic
22693
Molecules 2015, 20, 22691–22702
part of the aminoguanidine moiety [39]. These bands confirm the functionalization of the betulonic
acid, and the results are also correlated with the ones obtained by thermal analysis.
2.2.2. Thermal Analysis of Decomposition in Air
TG/DTG/HF analysis was used to describe the thermal stability and degradation of the
synthesized compounds in an oxidative air atmosphere. The first mass loss step, occurring at
low temperatures, is dehydration. After that, partial decomposition and the total decomposition
of the organic structure take place. Most processes are poorly separated from each other, since
the decomposition is clearly multistage, with overlapping processes. The thermal properties of
the synthesized triterpenic compounds were evaluated by TG, DTG and HF. TG/DTG/HF curves
providing information about the thermal degradation of the compounds are shown in Figure 3a–d.
The thermoanalytical curves vary in all four cases.
In the case of derivative C1, the water elimination takes place in the temperature range 57–184 ˝C,
with a maximum on the DTG curve at 170 ˝C and ∆m = 9.7%. The next thermal process defines the
melting of the compound, which takes place with decomposition (∆m = 16.8%; DTGmax = 263 ˝C
and HFmax = 264 ˝C). This melting temperature in good agreement with the value obtained using the
Boetius apparatus (Tmelting = 274–277 ˝C).
Figure 3. Thermoanalytical TG/DTG/HF data recorded in air atmosphere up to 500 ˝C for compounds
(a) C1; (b) C2; (c) C3 and (d) C4.
After that, an intensive thermodegradation takes place, with a 73.3% mass loss and characterized
by several peaks on the DTG curve at 410, 419, 428 and 444 ˝C, respectively. The HF curve has a strong
upward slope defining a strongly exothermic effect which accompanies the thermal degradation of the
triterpenic structure (Figure 3a).
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In the case of the functionalized compound C2, the mass loss starts from ~118 ˝C, according to
the thermogravimetric curve. After recrystallization, the observed melting point is in good agreement
with the one mentioned in literature (223–225 ˝C) [34]. Melting (acc. to Boetius between 225–229 ˝C) is
also revealed by the thermoanalytical technique, and takes place with decomposition (HFmax = 228 ˝C,
∆m = 9.8%). In the next temperature range, derivative C2 showed a pyrolitic decomposition involving
more successive processes. In the temperature range of 287 to 406 ˝C, there was a 42.7% mass loss and
between 406 and 500 ˝C, the mass loss was 39.5%, leading to a final mass of approx. 0% (Figure 3b).
As shown in Figure 3c, the thermal decomposition of C3 takes place in five degradation stages.
The first mass loss corresponds to a dehydration process. The water loss takes place in the temperature
range of 95–176 ˝C and corresponds to a mass loss of 3.4%. After this process, an endothermic peak
appears on the HF curve at 183 ˝C, highlighting the melting (no mass loss is observed on the TG
curve). The total decomposition of C3 starts above 200˝. After water release, the fragmentation of the
triterpenic compound starts. The first mass loss after melting represents 5.5% and is characterized by
a sharp peak on DTG curve with maximum at 224 ˝C. In the temperature range of the degradation
process (203–500 ˝C), several exothermal processes are revealed by the analysis of the HF curve. Above
333 ˝C, the decomposition of this compound is highly exothermic and the final degradation occurs at
488 ˝C, leaving a residue mass of ~0.05%.
The fourth analyzed compound (C4) is the most stable, with its decomposition starting at 245 ˝C.
The first step in the TG curve ends at 289 ˝C with a mass loss of 14% and corresponds with a defined
peak on the DTG curve with a maximum at 274 ˝C. The mass loss process is a continous one until
500 ˝C when the complete mass loss took place. The steps can be separated only on the basis of the DTG
curve. The second step begins at 289 and ends at 315 ˝C with a mass loss of 11% and it is assigned to
the oxydation of the triterpenic structure of the compound being accompanied by an strong exothermic
peak at 312 ˝C (exothermic combustion). Finally, for the last stage of degradation (315–500 ˝C range), it
can be assumed that the entire structure of the analyzed compound is totally oxidized and eliminated
as volatile compounds leaving a small residue with ∆m « 0.1% (Figure 3d).
2.3. Biological Activities
The results of the in vitro tests are displayed in Figures 4–7; all results were graphically presented
as comparisons with a known antiproliferative compound of similar structure, betulin. The analysis
was conducted in two concentrations as described in previous studies [40].
All four tested compounds are chemical derivatives obtained by the modulation of the
C-3 carbonyl group of betulonic acid, a triterpene compound proven as active against several
tumor cell lines, such as MGC-803–human gastric cancer, PC3–prostatic cancer and MCF7–breast
adenocarcinoma [41]. The related compounds, betulin and betulinic acid were thoroughly studied
by our research group, which revealed the important antiproliferative activities on the A431, MCF7
and HeLa tumor cell lines [42]; also, significant in vitro antitumor effects were reported against other
various cell lines [43,44]. In addition, betulin (Bet) was evaluated as antiangiogenic agent on the
same three cell lines, A431, HeLa and MCF7, in a study that also involved establishing the dose-effect
relationship [42]. The results showed a high specificity of betulin against cervical (HeLa) and skin
(A431) cancer accompanied by a significant activity against breast adenocarcinoma (MCF7). Based on
previous findings, betulin (Bet) was used as positive control in the current study which also involves
three previously studied tumor cell lines.
Derivative C1 revealed weaker cytotoxic effects on all four cell lines as compared to pure betulin,
regardless of the concentration involved (Figure 4). Moreover, the cytotoxic activity is completely
absent on the A431 cell line when the lower concentration was used, and even at higher concentration
the inhibitory activity against this cancer cell line of C1 was insignificant. On both HeLa and MCF7
cell lines, the cell viability was significantly reduced in a concentration-independent manner, thus
revealing an external limitation of the anticancer effect of C1, presumably its poor water solubility.
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A dose-activity relationship was noticed on the A2780 cell line; however, the results reveal weaker
inhibitory activity as compared to pure betulin.
Figure 4. The results of the in vitro tests for C1 vs. control group (Bet) *, **, *** indicate p < 0.05, p < 0.01,
and p < 0.001.
Compound C2 revealed a strong cytotoxic activity comparable to betulin on the A2780 cell line
when used at the lower concentration, and even higher than betulin when the higher concentration
was used; the compound also causes a significant inhibitory process against the HeLa and MCF7 cell
lines (Figure 5). By contrast, the cytotoxic activity is practically insignificant on A431 when the lower
concentration is applied; a strong inhibitory activity can be noticed however for higher concentrations.
Therefore, one can state that this compound possesses an important antitumoral/cytotoxic effect on
certain tumor cell lines, highly dependent on its concentration.
Figure 5. The results of the in vitro tests for C2 vs. control group (Bet) *, **, *** indicate p < 0.05, p < 0.01,
and p < 0.001.
Compound C3 displayed a quantifiable inhibitory activity against all tested cell lines; however,
the results are not very promising in comparison to pure betulin, which shows stronger cytotoxic
activity at both concentrations. As depicted in Figure 6, the cytotoxic effect of both compounds is
developed in a dose-relationship manner. The highest activity manifested by the compounds’ lower
concentrations occurs on HeLa cells, in contrast to the higher concentrations that were relevant against
ovarian carcinoma (A2780). For the MCF-7 (breast carcinoma) cell line the results show a similar
activity for both concentrations, comparable to the one noticed against ovarian carcinoma (A2780).
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Figure 6. The results of the in vitro tests for C3 vs. control group (Bet) *, **, *** indicate p < 0.05, p < 0.01,
and p < 0.001.
Compound C4 revealed significant cytotoxic effects against all types of cell lines involved in the
study; at the lower concentration, it proved to have comparable inhibitory activity to pure betulin on
the HeLa and MCF7 cell lines, while no activity was noticed against the A431 cell line. The A2780 cell
line proved to be the most sensitive to this compound, the inhibition percentage reaching 100% for the
higher concentration while at the lower concentration, the compound remains more active than pure
betulin (Figure 7).
Figure 7. The results of the in vitro tests for C4 vs. control group (Bet) *, **, *** indicate p < 0.05, p < 0.01,
and p < 0.001.
The results show that the chemical functionalization of the parent compound led to several
molecules with cytotoxic potential, the most promising being C4; we may assume that the water
solubility of the tested compounds is an important factor to be considered in future studies due to the
large variations noticed in terms of in vitro activity.
3. Experimental Section
3.1. General Information
All reagents and solvents were commercial products of Merck (Darmstadt, Germany) and used
without further purification. Betulonic acid used as starting material was previously prepared and
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characterized by appropriate instrumental techniques in our laboratory, and the results were already
published [33]. Reduced-pressure evaporation of solvents was realized using a R-200 rotary evaporator
(Büchi, Flawil, Switzerland) equipped with a Büchi heating bath B-490 and coupled to a Rotavac
vacuum pump. Thin-layer chromatography (TLC) was performed with silica gel-coated plates 60
F254 (Merck) using hexane–ethyl acetate 6:4 (v:v) and hexane–ethyl acetate 1:1 (v:v) as eluants. The
chromatographic spots were revealed by exposure to a mixture of H2SO4 5%, ammonium wolframate
5% and cerium sulphate 0.2% and/or UV light irradiation (λ = 254 nm). Melting points were
determined on a Böetius PHMK (Veb Analytik, Dresden, Germany) instrument and are uncorrected.
The percentages of C, H and N were obtained by means of elemental analysis using a El Cube apparatus
(Vario, Hanau, Germany). The thermal stabilities of the synthetized compounds were determined on
a DIAMOND thermo-balance (Perkin Elmer, Waltham, MA, USA) by recording the corresponding
thermoanalytical TG, DTG and HF curves. The samples (weighing between 6.2 and 8.6 mg) were
heated in aluminum crucible between 25 and 500 ˝C in a dynamic air atmosphere (100 mL¨min´1)
with a heating rate β of 10 ˝C¨min´1. For determining the thermal effects, the DTA data (in µV) were
converted to HF (Heat Flow) data (mW). In order to assure the reproducibility of the TG study, each
analysis was repeated three times. The results were practically identical. FTIR spectra were recorded
on a JASCO FTIR/670plus device (Jasco, Easton, MD, USA) using the KBr pellet dispersion method.
The data was collected in the 4000–400 cm´1 range. Spectra were built up after 36 acquisitions for
each spectrum.
3.2. Synthesis and Characterization
All the syntheses started from betulonic acid (BetO), which was dissolved in the minimum
amount of solvent (anhydrous pyridine for C1 and C2, absolute ethanol for C4), then treated with
aminoguanidine hydrogen carbonate (AmgH, for C1), hydroxylamine hydrochloride (HAH, for
C2), or thiosemicarbazide (TSC, for C4). The mixtures were refluxed (C1 and C4) or stirred at
room temperature (C2). After distilation under reduced pressure, the derivatives were purified by
recrystallisation of the crude product from ethanol (C1, C4) or previously dissolved in chloroform and
washed with water (C2). Derivative C3 was obtained in cold (0 ˝C) anhydrous toluene under inert gas,
by treating a mixture of n-butylamine (nBuA) with titanium (IV) chloride (TiCl4) in a 5.3:1 nBuA:TiCl4
molar ratio, with BetO (molar ratio TiCl4:BetO 1:0.75). After heating under reflux for 7 h and distilling
to dryness under reduced pressure, the crude compound was suspended in ethyl acetate, washed
twice with 15% HCl, then distilled water and dried over anhydrous Na2SO4. The crude compound
was recrystallized from ethanol. The physico-chemical characteristics of C1–C4 are listed in Table 1.
3.3. Biological Activity
The compounds’ cytotoxic effects were evaluated using a MTT ([3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide]) colorimetric assay and was performed on four human cell lines
(obtained from ECACC; Salisbury, UK): HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma),
A431 (skin epidermoid carcinoma) and A2780 (human ovarian carcinoma) [45]. The cells were
cultivated by applying minimal essential medium supplemented with 10% fetal bovine serum, 1%
non-essential amino acids and an antibiotic/antimycotic mixture. All media and supplements were
obtained from PAA Laboratories (Pasching, Austria). The cells were grown in a humidified atmosphere
of 5% CO2 at 37 ˝C. Cancer cells (5000/well) were seeded onto a 96-well microplate and attached
to the bottom of the well overnight. On the second day, 200 µL of new medium containing the test
substances were added. After 72 h incubation, the living cells were assayed by the addition of 20 µL of
5 mg/mL MTT solution. MTT was converted by the intact mitochondrial reductase and precipitated as
its formazan crystals during a 4 h contact period. The medium was then removed, and the precipitated
crystals were dissolved in 100 µL dimethyl sulfoxide (DMSO) under stirring for 60 min. Finally, the
reduced MTT was spectrophotometrically analyzed at 545 nm, using a microplate reader; wells with
untreated cells were used as controls. All in vitro experiments were carried out on two independent
22698
Molecules 2015, 20, 22691–22702
microplates with at least five parallel wells; the entire MTT evaluation was conducted under the same
conditions for all samples (time, preparation method). Stock solutions of the tested substances (10 mM)
were prepared using DMSO as solvent; the highest DMSO concentration (0.3%) was proven to not
have any significant effect on cell proliferation.
Table 1. The physico-chemical characteristics of the obtained functionalized derivatives C1–C4.
Structure Analytical Data
3-2-Carbamimidoylhydrazonolup-20(29)-en-28-oic acid (C1). White
crystalline solid (yield η = 66.7%), m.p. (Boetius) = 274–277 ˝C; FTIR
(KBr, cm´1): 3442, 3352, 3175, 3070, 2946, 2867, 1680, 1642, 1457,
1537, 1455, 1375, 1184, 989, 882, 749, 703, 617. Elemental Analysis
(Calcd./Found) for C31H50N4O2, M = 510.75 g/mol: C = 72.90%,
H = 9.87%, N = 10.97%; Found: C = 73.04%, H = 9.91%, N = 11.07%
3-Hydroxyiminolup-20(29)-en-28-oic acid (C2). White crystalline
solid (yield η = 72.4%), m.p. (Boetius) = 210 ˝C (phase transition);
219–224 ˝C (crude); m.p.(Boetius) = 225–229 ˝C (EtOH); FTIR (KBr,
cm´1): 3283, 3073, 2946, 2869, 1697, 1642, 1455, 1385, 1376, 1320,
1267, 1233, 1188, 1144, 1023, 945, 885, 795, 746, 665, 567, 544, 501;
Elemental Analysis (Calcd./Found) for C30H47NO3,
M = 469.70 g/mol: C = 76.71%, H = 10.09%, N = 2.98%; Found:
C = 76.15%, H = 10.23%, N = 2.64%
3-Butyliminolup-20(29)-en-28-oic acid (C3). Pale yellow solid (yield
η = 73.4%), m.p. (Boetius) = 145–150 ˝C; FTIR (KBr, cm´1): 3072,
2986, 2940, 2868, 1694, 1642, 1454, 1375, 1279, 1233, 1180, 1110, 1024,
882, 744, 543; Elemental Analysis (Calcd./Found) for C34H55NO2,
M = 509.81 g/mol: C = 80.10%, H = 10.87%, N = 2.75%; Found:
C = 80.98%, H = 11.29%, N = 2.82%
3-(2-Carbamothioylhydrazono)lup-20(29)-en-28-oic acid (C4). White
solid (yield η = 28.1%), m.p.(Boetius) >330 ˝C; FTIR (KBr, cm´1):
3449, 3303, 3245, 2940, 2867, 1690, 1640, 1515, 1481, 1458, 1389, 1373,
1236, 1204, 973, 894, 602, 495; Elemental Analysis (Calcd./Found) for
C31H49N3O2S, M = 527.80 g/mol: C = 70.54%, H = 9.36%, N = 7.96%;
Found: C = 70.15%, H = 9.59%, N = 8.01%
3.4. Statistical Analysis
Paired Student’s t tests or One-way ANOVA were used to determine the statistical differences
between various experimental and control groups.
4. Conclusions
In this paper, we presented the functionalization of betulonic acid, which is a semi-synthetic
derivative obtained by selective oxidation of the naturally abundantly occurring betulin. The
functionalization of betulonic acid was carried out at the 3-oxo position and aimed at the
condensation with several amino compounds like aminoguanidine, hydroxylamine, n-butylamine and
thiosemicarbazide, used in molar ratios from 1:1 up to 1:2. All the compounds were characterized by
physico-chemical tools, including elemental analysis, FTIR spectroscopy and thermogravimetry and
later assayed for the cytotoxic activity. The in vitro biological evaluation led to the conclusion that the
most promising compound is 3-(2-carbamothioylhydrazono)-lup-20(29)-en-28-oic acid (C4).
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